Francis LeeDirector, Tumor Pharmacology and Experimental Therapeutics Bristol-Myers Squibb
Hui GaoResearch Investigator III, Oncology Pharmacology Novartis
Deepak SampathSenior Scientist, Translational Oncology, Genentech
Corinne ReimerAssociate Director, In Vivo Pharmacology, Oncology iMed Science Unit AstraZeneca
The 3rd Annual Tumor Models Boston recently ran in July 2014 with over 70 pre-clinical oncologists and tumor model developers in attendance to network, interact and find solutions to enable them to make more clinically relevant predictions and improve the translational success of candidates into human clinical trials.
Attendees discovered industry defining information, effective preclinical strategies and expanded their network to achieve effective analysis and interpretation of data derived from tumour models.
Here's a snapshot of what was covered:
What's next for the Tumor Model Community?
“Very valuable and useful information. One of the best meetings I’ve ever attended.” Millennium
“Very good scientific content and stimulating discussions” Metabolon
“The talks were high quality and the interaction among participants was excellent.” Genentech
“Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues” Sanofi Aventis
“The focused meetings are very useful. It brings the right people together” Zymeworks
“I thought the meeting had exceeded my expectations and found it an excellent forum to open discuss the utility and challenges of our current tumor models.” Deepak Sampath, Senior Scientist, Translational Oncology, Genentech